Liposomal delivery of functional transmembrane ion channels into the cell membranes of target cells; a potential approach for the treatment of channelopathies.


Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
15 Jun 2020
Historique:
received: 18 09 2019
revised: 24 10 2019
accepted: 25 10 2019
pubmed: 23 11 2019
medline: 10 2 2021
entrez: 23 11 2019
Statut: ppublish

Résumé

Defects in transmembrane ion channels underlie many disorders, commonly known as channelopathies. Current therapies are mostly symptomatic and do not treat the underlying cause. Here, we demonstrate the delivery of functional ion channels in protein form into the membrane of target cells using fusogenic proteoliposomes. The glycine receptor (GlyR) was adopted as a model channel. HEK293 cells were transfected with GlyR and GlyR-rich cell membrane fragments (CMF) were incorporated into fusogenic liposomes. Proteoliposomes were generated using 1,2-dioleoylphosphoethanolamine (DOPE) as the fusogenic lipid, lecithin, 1,2-distearoylphosphoethanolamine (DSPE), and cholesterol (Chol). Three formulations were prepared Non-fuse (2.5:0.5 Lecithin: Chol), Fuse1 (1.25:0.25:0.25:0.25) and Fuse2 (1.25:0.5:0.5:0.25 Lecithin: DOPE: DSPE: Chol). Proteoliposomes were assessed for their ability to (1) incorporate GlyR rich CMF (2) fuse with L929 fibroblast cell membrane and (3) deliver functional GlyR to these cells. All formulations were capable of integrating CMF, with Fuse2 showing highest CMF incorporation (1.2 and 1.4 folds relative to Non-fuse and Fuse1 respectively). All liposomes showed ability to fuse with the fibroblast cell membrane, with Fuse2 showing highest fusion. Patch-clamp analysis demonstrated successful delivery of functional GlyR into the fibroblast cell membrane. Thus, proof of principle was established for the use of liposomes to deliver functional ion channels to living cells.

Identifiants

pubmed: 31756462
pii: S0141-8130(19)37521-X
doi: 10.1016/j.ijbiomac.2019.10.238
pii:
doi:

Substances chimiques

Liposomes 0
Receptors, Glycine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1080-1089

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors report no conflict of interests.

Auteurs

Shahenda Ramadan (S)

Department of Pharmaceutical Technology, The German University in Cairo (GUC), Cairo, Egypt.

Salma N Tammam (SN)

Department of Pharmaceutical Technology, The German University in Cairo (GUC), Cairo, Egypt. Electronic address: Salma.nabil@guc.edu.eg.

Maryam A Shetab Boushehri (MA)

Department of Pharmaceutics, University of Bonn, Bonn 53121, Germany.

Hans-Georg Breitinger (HG)

Department of Biochemistry, The German University in Cairo (GUC), Cairo, Egypt.

Ulrike Breitinger (U)

Department of Biochemistry, The German University in Cairo (GUC), Cairo, Egypt.

Samar Mansour (S)

Department of Pharmaceutical Technology, The German University in Cairo (GUC), Cairo, Egypt.

Alf Lamprecht (A)

Department of Pharmaceutics, University of Bonn, Bonn 53121, Germany; PEPITE EA4267, Univ. Bourgonge Franch-Comte, Besançon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH